
  
    
      
        
        The_DT biogerontologist_NN David_NNP Sinclair_NNP and_CC the_DT bioethicist_NN Leon_NNP Kass_NNP recently_RB locked_VBD horns_NNS
        in_IN a_DT radio_NN debate_NN (_( http_NN :_: /_NN /_NN www_NN ._. theconnection_NN ._. org_NN /_NN shows_VBZ /_NN 2004_CD /_NN 01_CD /_NN 20040106_CD __NN b_SYM __NN main_JJ ._. asp_NN )_) on_IN human_JJ
        life_NN extension_NN that_WDT was_VBD remarkable_JJ for_IN one_CD thing_NN :_: on_IN the_DT key_JJ issue_NN ,_, Kass_NNP was_VBD right_NN and_CC
        Sinclair_NNP wrong_NN ._. Sinclair_NNP suggested_VBD ,_, as_IN have_VBP other_JJ experts_NNS ,_, including_VBG his_PRP$ mentor_NN Lenny_NNP
        Guarente_NNP and_CC the_DT National_NNP Institute_NNP on_IN Aging_NNP advisory_JJ council_NN member_NN Elizabeth_NNP Blackburn_NNP ,_,
        that_IN Kass_NNP and_CC other_JJ bioconservatives_NNS are_VBP creating_VBG a_DT false_JJ alarm_NN about_IN life_NN extension_NN ,_,
        because_IN only_RB a_DT modest_JJ (_( say_VBP ,_, 30_CD %_NN )_) increase_NN in_IN human_JJ life_NN span_NN is_VBZ achievable_JJ by_IN biomedical_JJ
        intervention_NN ,_, whereas_IN Kass_NNP 's_POS apprehensions_NNS concern_NN extreme_JJ or_CC indefinite_JJ life_NN extension_NN ._.
        Kass_NNP retorted_JJ that_DT science_NN is_VBZ n't_RB like_VB that_DT :_: modest_JJ success_NN tends_VBZ to_TO place_VB the_DT bit_NN between_IN
        our_PRP$ teeth_NNS and_CC can_MD often_RB result_VB in_IN advances_NNS far_RB exceeding_VBG our_PRP$ expectations_NNS ._.
        
        Coping_NNP with_IN Methuselah_NNP consists_VBZ of_IN seven_CD essays_NNS ,_, mostly_RB on_IN the_DT economics_NNS
        of_IN life_NN extension_NN but_CC also_RB including_VBG one_CD essay_NN surveying_VBG the_DT biology_NN of_IN aging_VBG and_CC one_CD on_IN
        the_DT ethics_NNS of_IN life_NN extension_NN ._. The_DT economic_JJ issues_NNS addressed_VBN are_VBP wide_JJ ranging_VBG ,_, including_VBG
        detailed_JJ analysis_NN of_IN the_DT balance_NN between_IN wealth_NN creation_NN by_IN the_DT employed_VBN and_CC wealth_NN
        consumption_NN in_IN pensions_NNS and_CC health_NN care_NN ;_: most_JJS chapters_NNS focus_VBP on_IN the_DT United_NNP States_NNPS ,_, but_CC the_DT
        closing_VBG chapter_NN discusses_NNS these_DT issues_NNS in_IN a_DT global_JJ context_NN ._. Each_DT essay_NN is_VBZ followed_VBN by_IN a_DT
        short_JJ commentary_NN by_IN another_DT distinguished_VBN author_NN ._. Within_IN their_PRP$ own_JJ scope_NN ,_, all_DT of_IN these_DT
        contributions_NNS are_VBP highly_RB informative_JJ and_CC rigorous_JJ ._. Dishearteningly_NNP ,_, however_RB ,_, all_DT echo_VBP
        Sinclair_NNP 's_POS views_NNS about_IN the_DT limited_JJ prospects_NNS for_IN life_NN extension_NN in_IN the_DT coming_VBG decades_NNS ._. In_IN
        my_PRP$ opinion_NN ,_, they_PRP make_VBP three_CD distinct_JJ oversights_NNS ._.
        The_DT first_JJ concerns_NNS current_JJ science_NN ._. Sinclair_NNP and_CC several_JJ other_JJ prominent_JJ gerontologists_NNS
        are_VBP presently_RB seeking_VBG human_JJ therapies_NNS based_VBN on_IN the_DT long-standing_JJ observation_NN that_IN lifelong_JJ
        restriction_NN of_IN caloric_JJ intake_NN considerably_RB extends_VBZ both_DT the_DT healthy_JJ and_CC total_JJ life_NN span_NN of_IN
        nearly_RB all_DT species_NNS in_IN which_WDT it_PRP has_VBZ been_VBN tried_VBN ,_, including_VBG rodents_NNS and_CC dogs_NNS ._. Drugs_NNS that_WDT
        elicit_NN the_DT gene_NN expression_NN changes_NNS that_WDT result_NN from_IN caloric_JJ restriction_NN might_MD ,_, these_DT
        workers_NNS assert_VBP ,_, extend_VB human_JJ life_NN span_NN by_IN something_NN approaching_VBG the_DT same_JJ proportion_NN as_IN seen_VBN
        in_IN rodents—_NN 20_CD %_NN is_VBZ often_RB predicted—without_NN impacting_VBG quality_NN of_IN life_NN ,_, and_CC even_RB when_WRB
        administered_VBN starting_VBG in_IN middle_JJ age_NN ._. They_PRP assiduously_RB stress_VBP ,_, however_RB ,_, that_DT anything_NN beyond_IN
        this_DT degree_NN of_IN life_NN extension_NN is_VBZ inconceivable_JJ ._.
        I_PRP agree_VBP with_IN these_DT predictions_NNS in_IN two_CD respects_VBZ :_: that_IN the_DT degree_NN of_IN life_NN extension_NN
        achieved_VBN by_IN first-generation_JJ drugs_NNS of_IN this_DT sort_NN may_MD well_RB approach_VB the_DT (_( currently_RB unknown_JJ )_)
        amount_NN elicitable_JJ by_IN caloric_JJ restriction_NN itself_PRP in_IN humans_NNS ,_, and_CC that_IN it_PRP is_VBZ unlikely_JJ to_TO be_VB
        much_RB exceeded_VBN by_IN later_JJ drugs_NNS that_WDT work_NN the_DT same_JJ way_NN ._. In_IN two_CD other_JJ ways_NNS ,_, however_RB ,_, I_PRP claim_VBP
        they_PRP are_VBP incorrect_JJ ._. The_DT first_JJ error_NN is_VBZ the_DT assumption_NN of_IN proportionality_NN :_: I_PRP have_VBP recently_RB
        argued_VBN (_( de_IN Grey_NNP 2004_CD )_) ,_, from_IN evolutionary_JJ considerations_NNS ,_, that_IN longer-lived_JJ species_NNS will_MD
        show_VB a_DT smaller_JJR maximal_NN proportional_JJ life-span_JJ extension_NN in_IN response_NN to_TO starvation_NN ,_, probably_RB
        not_RB much_RB more_JJR than_IN the_DT same_JJ 
        absolute_JJ increase_NN seen_VBN in_IN shorter-lived_JJ species_NNS ._. The_DT second_JJ error_NN is_VBZ the_DT
        assertion_NN that_IN no_DT other_JJ type_NN of_IN intervention_NN can_MD do_VB better_JJR ._. In_IN concert_NN with_IN other_JJ
        colleagues_NNS whose_WP$ areas_NNS of_IN expertise_NN span_NN the_DT relevant_JJ fields_NNS ,_, I_PRP have_VBP described_VBN (_( de_IN Grey_NNP et_CC
        al_NN ._. 2002_CD ,_, 2004_CD )_) a_DT strategy_NN built_VBN around_IN the_DT actual_JJ 
        repair_NN (_( not_RB just_RB retardation_NN of_IN accumulation_NN )_) of_IN age-related_JJ molecular_JJ
        and_CC cellular_JJ damage—consisting_VBG of_IN just_RB seven_CD major_JJ categories_NNS of_IN ‘ rejuvenation_NN therapy_NN’
        (_( Table_NNP 1_LS )_) —_NN that_WDT appears_VBZ technically_RB feasible_JJ and_CC ,_, by_IN its_PRP$ nature_NN ,_, is_VBZ indefinitely_RB extensible_JJ
        to_TO greater_JJR life_NN spans_NNS without_IN recourse_NN to_TO further_VB conceptual_JJ breakthroughs_NNS ._.
        The_DT second_JJ oversight_NN made_VBD both_DT by_IN the_DT contributors_NNS to_TO 
        Coping_NNP with_IN Methuselah_NNP and_CC by_IN other_JJ commentators_NNS is_VBZ demographic_JJ ._. Life_NN
        expectancy_NN is_VBZ typically_RB defined_VBN in_IN terms_NNS of_IN what_WP demographers_NNS call_VBP a_DT period_NN survival_NN curve_NN ,_,
        which_WDT is_VBZ a_DT purely_RB artificial_JJ construction_NN derived_VBN from_IN the_DT proportions_NNS of_IN those_DT of_IN each_DT age_NN
        at_IN the_DT start_NN of_IN a_DT given_VBN year_NN who_WP die_VBP during_IN that_DT year_NN ._. The_DT ‘ life_NN expectancy_NN’ of_IN the_DT
        ‘ population_NN’ thus_RB described_VBD is_VBZ that_IN of_IN a_DT hypothetical_JJ population_NN whose_WP$ members_NNS live_VBP all_DT
        their_PRP$ lives_NNS with_IN the_DT mortality_NN risk_NN at_IN each_DT age_NN that_IN the_DT real_JJ people_NNS of_IN that_DT age_NN
        experienced_VBN in_IN the_DT year_NN of_IN interest_NN ._. The_DT remaining_VBG life_NN expectancy_NN of_IN someone_NN aged_VBN 
        N_NNP in_IN that_DT year_NN is_VBZ more_JJR than_IN this_DT life_NN expectancy_NN minus_CC 
        N_NNP for_IN two_CD reasons_NNS :_: one_CD mathematical_JJ (_( what_WP one_CD actually_RB wants_VBZ ,_, roughly_RB ,_, is_VBZ
        the_DT age_NN to_TO which_WDT the_DT probability_NN of_IN survival_NN is_VBZ half_NN that_IN of_IN survival_NN to_TO 
        N_NNP )_) and_CC one_CD biomedical_JJ (_( mortality_NN rates_NNS at_IN each_DT age_NN ,_, especially_RB advanced_VBD
        ages_NNS ,_, tend_VBP to_TO fall_VB with_IN time_NN )_) ._. My_PRP$ spirits_NNS briefly_NN rose_VBD on_IN reading_NN Aaron_NNP and_CC Harris_NNP 's_POS
        explicit_JJ statement_NN (_( p_NN ._. 69_CD )_) of_IN the_DT latter_JJ reason_NN ._. Unfortunately_RB ,_, they_PRP did_VBD n't_RB discuss_VB what_WP
        would_MD happen_VB if_IN age-specific_JJ mortality_NN rates_NNS fell_VBN by_IN more_JJR than_IN 2_CD %_NN per_IN year_NN ._. An_DT interesting_JJ
        scenario_NN was_VBD thus_RB unexplored_JJ :_: that_IN in_IN which_WDT mortality_NN rates_NNS fall_VBP so_RB fast_RB that_IN people_NNS 's_POS 
        remaining_VBG (_( not_RB merely_RB total_JJ )_) life_NN expectancy_NN increases_NNS with_IN time_NN ._. Is_VBZ this_DT
        unimaginably_RB fast_RB ?_. Not_RB at_IN all_DT :_: it_PRP is_VBZ simply_RB the_DT ratio_NN of_IN the_DT mortality_NN rates_NNS at_IN consecutive_JJ
        ages_NNS (_( in_IN the_DT same_JJ year_NN )_) in_IN the_DT age_NN range_NN where_WRB most_JJS people_NNS die_VBP ,_, which_WDT is_VBZ only_RB about_IN 10_CD %_NN per_IN
        year_NN ._. I_PRP term_NN this_DT rate_NN of_IN reduction_NN of_IN age-specific_JJ mortality_NN risk_NN ‘ actuarial_JJ escape_NN
        velocity_NN’ (_( AEV_NNP )_) ,_, because_IN an_DT individual_NN 's_POS remaining_VBG life_NN expectancy_NN is_VBZ affected_VBN by_IN aging_VBG and_CC
        by_IN improvements_NNS in_IN life-extending_JJ therapy_NN in_IN a_DT way_NN qualitatively_RB very_RB similar_JJ to_TO how_WRB the_DT
        remaining_VBG life_NN expectancy_NN of_IN someone_NN jumping_VBG off_IN a_DT cliff_NN is_VBZ affected_VBN by_IN ,_, respectively_RB ,_,
        gravity_NN and_CC upward_RB jet_NN propulsion_NN (_( Figure_NN 1_LS )_) ._.
        The_DT escape_NN velocity_NN cusp_NN is_VBZ closer_JJR than_IN you_PRP might_MD guess_VB ._. Since_IN we_PRP are_VBP already_RB so_RB long_RB
        lived_VBD ,_, even_RB a_DT 30_CD %_NN increase_NN in_IN healthy_JJ life_NN span_NN will_MD give_VB the_DT first_JJ beneficiaries_NNS of_IN
        rejuvenation_NN therapies_NNS another_DT 20_CD years—an_NN eternity_NN in_IN science—to_NN benefit_NN from_IN
        second-generation_JJ therapies_NNS that_WDT would_MD give_VB another_DT 30_CD %_NN ,_, and_CC so_RB on_IN ad_NN infinitum_NN ._. Thus_RB ,_, if_IN
        first-generation_JJ rejuvenation_NN therapies_NNS were_VBD universally_RB available_JJ and_CC this_DT progress_NN in_IN
        developing_VBG rejuvenation_NN therapy_NN could_MD be_VB indefinitely_RB maintained_VBN ,_, these_DT advances_NNS would_MD put_VB
        us_PRP beyond_IN AEV_NNP ._. Universal_JJ availability_NN might_MD be_VB thought_VBN economically_RB and_CC sociopolitically_RB
        implausible_JJ (_( though_IN that_DT conclusion_NN may_MD be_VB premature_JJ ,_, as_IN I_PRP will_MD summarise_NN below_IN )_) ,_, so_IN it_PRP 's_VBZ
        worth_JJ considering_VBG the_DT same_JJ question_NN in_IN terms_NNS of_IN life-span_JJ 
        potential_JJ (_( the_DT life_NN span_NN of_IN the_DT luckiest_NN people_NNS )_) ._. Figure_NN 1_CD again_RB
        illustrates_VBZ this_DT :_: those_DT who_WP get_VBP first-generation_JJ therapies_NNS only_RB just_RB in_IN time_NN will_MD in_IN fact_NN
        be_VB unlikely_JJ to_TO live_VB more_JJR than_IN 20_CD –_NN 30_CD years_NNS more_JJR than_IN their_PRP$ parents_NNS ,_, because_IN they_PRP will_MD spend_VB
        many_JJ frail_JJ years_NNS with_IN a_DT short_JJ remaining_VBG life_NN expectancy_NN (_( i_NNP ._. e_SYM ._. ,_, a_DT high_JJ risk_NN of_IN imminent_JJ
        death_NN )_) ,_, whereas_IN those_DT only_RB a_DT little_JJ younger_JJR will_MD never_RB get_VB that_IN frail_JJ and_CC will_MD spend_VB rather_RB
        few_JJ years_NNS even_RB in_IN biological_JJ middle_JJ age_NN ._. Quantitatively_NNP ,_, what_WP this_DT means_VBZ is_VBZ that_IN if_IN a_DT 10_CD %_NN
        per_IN year_NN decline_NN of_IN mortality_NN rates_NNS at_IN all_DT ages_NNS is_VBZ achieved_VBN and_CC sustained_VBN indefinitely_RB ,_,
        then_RB the_DT first_JJ 1000_CD -_: year-old_JJ is_VBZ probably_RB only_RB 5_CD –_NN 10_CD years_NNS younger_JJR than_IN the_DT first_JJ
        150_CD -_: year-old_JJ ._.
        The_DT third_JJ oversight_NN that_IN I_PRP observe_VBP in_IN contemporary_JJ commentaries_NNS on_IN life_NN extension_NN ,_, among_IN
        which_WDT 
        Coping_NNP with_IN Methuselah_NNP is_VBZ representative_NN ,_, is_VBZ the_DT most_RBS significant_JJ because_IN
        of_IN its_PRP$ urgency_NN ._. First-generation_NNP rejuvenation_NN therapies_NNS ,_, whenever_WRB they_PRP arrive_VBP ,_, will_MD surely_RB
        build_VB on_IN a_DT string_NN of_IN prior_JJ laboratory_NN achievements_NNS ._. Those_DT achievements_NNS ,_, it_PRP seems_VBZ to_TO me_PRP ,_,
        will_MD have_VB progressively_RB worn_JJ down_RB humanity_NN 's_POS evidently_RB desperate_JJ determination_NN to_TO close_VB its_PRP$
        eyes_NNS to_TO the_DT prospect_NN of_IN defeating_VBG its_PRP$ foremost_RB remaining_VBG scourge_NN anytime_RB soon_RB ._. The_DT problem_NN
        (_( if_IN we_PRP can_MD call_VB it_PRP that_IN )_) is_VBZ that_IN this_DT wearing-down_JJ may_MD have_VB been_VBN completed_VBN long_RB before_IN the_DT
        rejuvenation_NN therapies_NNS arrive_VBP ._. There_EX will_MD come_VB an_DT advance—probably_RB a_DT single_JJ laboratory_NN
        result—that_NN breaks_VBZ the_DT camel_NN 's_POS back_RB and_CC forces_NNS society_NN to_TO abandon_VB that_DT denial_NN :_: to_TO accept_VB
        that_IN the_DT risk_NN of_IN getting_VBG one_CD 's_POS hopes_VBZ up_RB and_CC seeing_VBG them_PRP dashed_VBD is_VBZ now_RB outweighed_VBN by_IN the_DT
        risk_NN of_IN missing_VBG the_DT AEV_NNP boat_NN by_IN inaction_NN ._. What_WP will_MD that_DT result_VB be_VB ?_. I_PRP think_VBP a_DT conservative_JJ
        guess_NN is_VBZ a_DT trebling_VBG of_IN the_DT remaining_VBG life_NN span_NN of_IN mice_NNS of_IN a_DT long-lived_JJ strain_NN that_WDT have_VBP
        reached_VBN two-thirds_NNS of_IN their_PRP$ normal_JJ life_NN span_NN before_IN treatment_NN begins_VBZ ._. This_DT would_MD possess_VB
        what_WP I_PRP claim_VBP are_VBP the_DT key_JJ necessary_JJ features_NNS :_: a_DT big_JJ life_NN extension_NN ,_, in_IN something_NN furry_NN and_CC
        not_RB congenitally_RB sick_JJ ,_, from_IN treatment_NN begun_VBN in_IN middle_JJ age_NN ._.
        It_PRP is_VBZ the_DT prospect_NN of_IN AEV_NNP ,_, of_IN course_NN ,_, that_WDT makes_VBZ this_DT juncture_NN so_RB pivotal_JJ ._. It_PRP seems_VBZ
        quite_RB certain_JJ to_TO me_PRP that_IN the_DT announcement_NN of_IN such_JJ mice_NNS will_MD cause_VB huge_JJ ,_, essentially_RB
        immediate_JJ ,_, society-wide_JJ changes_NNS in_IN lifestyle_NN and_CC expenditure_NN choices—in_NN a_DT word_NN ,_,
        pandemonium—resulting_VBG from_IN the_DT anticipation_NN that_IN extreme_JJ human_JJ life_NN extension_NN might_MD arrive_VB
        soon_RB enough_RB to_TO benefit_VB people_NNS already_RB alive_JJ ._. We_PRP will_MD probably_RB not_RB have_VB effective_JJ
        rejuvenation_NN therapies_NNS for_IN humans_NNS for_IN at_IN least_JJS 25_CD years_NNS ,_, and_CC it_PRP could_MD certainly_RB be_VB 100_CD
        years_NNS ._. But_CC given_VBN the_DT present_JJ status_NN of_IN the_DT therapies_NNS listed_VBN in_IN Table_NNP 1_CD ,_, we_PRP have_VBP ,_, in_IN my_PRP$
        view_NN ,_, a_DT high_JJ probability_NN of_IN reaching_VBG the_DT mouse_NN life_NN extension_NN milestone_NN just_RB described_VBD
        (_( which_WDT I_PRP call_VBP ‘ robust_JJ mouse_NN rejuvenation_NN’ )_) within_IN just_RB 
        ten_CD years_NNS ,_, given_VBN adequate_JJ and_CC focused_VBN funding_NN (_( perhaps_RB $_$ 100_CD million_CD per_IN
        year_NN )_) ._. And_CC nobody_NN in_IN 
        Coping_NNP with_IN Methuselah_NNP said_VBD so_RB ._. This_DT timeframe_NN could_MD be_VB way_NN off_RP ,_, of_IN
        course_NN ,_, but_CC as_IN Wade_NNP notes_NNS (_( p_NN ._. 57_CD )_) ,_, big_JJ advances_NNS often_RB occur_VBP much_JJ sooner_RBR than_IN most_JJS experts_NNS
        expect_VBP ._. Even_RB the_DT most_RBS obvious_JJ of_IN these_DT lifestyle_NN changes—greater_NN expenditure_NN on_IN traditional_JJ
        medical_JJ care_NN ,_, avoidance_NN of_IN socially_RB vital_JJ but_CC risky_JJ professions—could_NN severely_RB destabilise_NN
        the_DT global_JJ economy_NN ;_: those_DT better_RBR versed_JJ in_IN economics_NNS and_CC sociology_NN than_IN I_PRP would_MD doubtless_RB
        be_VB even_RB more_RBR pessimistic_JJ about_IN our_PRP$ ability_NN to_TO negotiate_VB this_DT period_NN smoothly_RB ._.
        Overpopulation_NNP ,_, probably_RB the_DT most_RBS frequently_RB cited_VBD drawback_NN of_IN curing_VBG aging_VBG ,_, could_MD not_RB
        result_VB for_IN many_JJ decades_NNS ,_, but_CC the_DT same_JJ cannot_NN be_VB said_VBD for_IN breadth_NN of_IN access_NN irrespective_RB of_IN
        ability_NN to_TO pay_VB :_: in_IN a_DT post-_NN 9_CD /_NN 11_CD world_NN ,_, restricted_VBN availability_NN of_IN rejuvenation_NN therapies_NNS
        resembling_VBG that_WDT seen_VBN today_NN with_IN AIDS_NNP drugs_NNS would_MD invite_VB violence_NN on_IN a_DT scale_NN that_IN ,_, shall_MD we_PRP
        say_VB ,_, might_MD be_VB worth_JJ trying_VBG to_TO avoid_VB ._.
        Am_NNP I_PRP ,_, then_RB ,_, resigned_VBD to_TO a_DT future_NN in_IN which_WDT countless_JJ millions_NNS are_VBP denied_VBN many_JJ decades_NNS of_IN
        life_NN by_IN our_PRP$ studied_VBN reluctance_NN to_TO plan_VB ahead_RB today_NN ?_. Not_RB quite_RB ._. The_DT way_NN out_IN is_VBZ pointed_VBN to_TO in_IN
        Lee_NNP and_CC Tuljapurkar_NNP 's_POS (_( 1997_CD )_) graph_NN of_IN the_DT average_JJ wealth_NN consumed_VBN and_CC generated_VBN by_IN an_DT
        individual_NN as_IN a_DT function_NN of_IN age_NN ,_, reproduced_VBD in_IN 
        Coping_NNP with_IN Methuselah_NNP (_( p_NN ._. 143_CD )_) ._. Once_RB AEV_NNP is_VBZ achieved_VBN ,_, there_EX will_MD be_VB no_DT
        going_VBG back_RB :_: rejuvenation_NN research_NN will_MD be_VB intense_JJ forever_RB thereafter_RB and_CC will_MD anticipate_VB
        and_CC remedy_VB the_DT life-threatening_JJ degenerative_JJ changes_NNS appearing_VBG at_IN newly_RB achieved_VBN ages_NNS with_IN
        ever-increasing_JJ efficacy_NN and_CC lead_VB time_NN ._. This_DT will_MD bring_VB about_IN the_DT greatest_JJS economic_JJ change_NN
        of_IN all_DT in_IN society_NN :_: the_DT elimination_NN of_IN retirement_NN benefits_NNS ._. Retirement_NN benefits_NNS are_VBP for_IN
        frail_JJ people_NNS ,_, and_CC there_EX wo_MD n't_RB 
        be_VB any_DT frail_JJ people_NNS ._. The_DT graph_NN just_RB mentioned_VBD amply_RB illustrates_VBZ how_WRB much_JJ
        wealth_NN will_MD be_VB released_VBN by_IN this_DT ._. My_PRP$ hope_VBP ,_, therefore_RB ,_, is_VBZ that_IN once_RB policy_NN makers_NNS begin_VBP to_TO
        realise_NN what_WP 's_VBZ coming_VBG they_PRP will_MD factor_VB in_IN this_DT eventual_JJ windfall_NN and_CC allocate_VBP sufficient_JJ
        short-term_JJ resources_NNS to_TO make_VB the_DT period_NN of_IN limited_JJ availability_NN of_IN rejuvenation_NN therapies_NNS
        brief_JJ enough_RB to_TO prevent_VB mayhem_NN ._. This_DT will_MD ,_, however_RB ,_, be_VB possible_JJ only_RB if_IN such_JJ resources_NNS
        begin_VBP to_TO be_VB set_VBN aside_RB long_RB enough_RB in_IN advance—and_NN we_PRP do_VBP n't_RB know_VB how_WRB long_JJ we_PRP have_VBP ._.
      
    
  
